|
1
|
Baldrick FR, Woodside JV, Elborn JS, Young
IS and McKinley MC: Biomarkers of fruit and vegetable intake in
human intervention studies: A systematic review. Crit Rev Food Sci
Nutr. 51:795–815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boeing H, Bechthold A, Bub A, Ellinger S,
Haller D, Kroke A, Leschik-Bonnet E, Müller MJ, Oberritter H,
Schulze M, et al: Critical review: Vegetables and fruit in the
prevention of chronic diseases. Eur J Nutr. 51:637–663. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lampe JW: Health effects of vegetables and
fruit: Assessing mechanisms of action in human experimental
studies. Am J Clin Nutr. 70 3 Suppl:S475–S490. 1999. View Article : Google Scholar
|
|
4
|
Gandini S, Merzenich H, Robertson C and
Boyle P: Meta-analysis of studies on breast cancer risk and diet:
The role of fruit and vegetable consumption and the intake of
associated micronutrients. Eur J Cancer. 36:636–646. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Y, Totsuka Y, Shan B, Wang C, Wei W,
Qiao Y, Kikuchi S, Inoue M, Tanaka H and He Y: Esophageal cancer in
high-risk areas of China: Research progress and challenges. Ann
Epidemiol. 27:215–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blot WJ, Li JY, Taylor PR, Guo W, Dawsey
S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al: Nutrition
intervention trials in Linxian, China: Supplementation with
specific vitamin/mineral combinations, cancer incidence, and
disease-specific mortality in the general population. J Natl Cancer
Inst. 85:1483–1492. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li S, Jiang S, Jiang W, Zhou Y, Shen XY,
Luo T, Kong LP and Wang HQ: Anticancer effects of crocetin in human
esophageal squamous cell carcinoma KYSE-150 cells. Oncol Lett.
9:1254–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li JY, Taylor PR, Li B, Dawsey S, Wang GQ,
Ershow AG, Guo W, Liu SF, Yang CS, Shen Q, et al: Nutrition
intervention trials in Linxian, China: Multiple vitamin/mineral
supplementation, cancer incidence, and disease-specific mortality
among adults with esophageal dysplasia. J Natl Cancer Inst.
85:1492–1498. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feige JN, Gelman L, Michalik L, Desvergne
B and Wahli W: From molecular action to physiological outputs:
Peroxisome proliferator-activated receptors are nuclear receptors
at the crossroads of key cellular functions. Prog Lipid Res.
45:120–159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Semple RK, Chatterjee VK and O'Rahilly S:
PPAR gamma and human metabolic disease. J Clin Invest. 116:581–589.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sporn MB, Suh N and Mangelsdorf DJ:
Prospects for prevention and treatment of cancer with selective
PPAR gamma modulators (SPARMs). Trends Mol Med. 7:395–400. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ondrey F: Peroxisome
proliferator-activated receptor gamma pathway targeting in
carcinogenesis: Implications for chemoprevention. Clin Cancer Res.
15:2–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rumi MA, Sato H, Ishihara S, Ortega C,
Kadowaki Y and Kinoshita Y: Growth inhibition of esophageal
squamous carcinoma cells by peroxisome proliferator-activated
receptor gamma ligands. J Lab Clin Med. 140:17–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hashimoto Y, Shimada Y, Itami A, Ito T,
Kawamura J, Kawabe A, Kaganoi J, Maeda M, Watanabe G and Imamura M:
Growth inhibition through activation of peroxisome
proliferator-activated receptor gamma in human oesophageal squamous
cell carcinoma. Eur J Cancer. 39:2239–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takashima T, Fujiwara Y, Hamaguchi M,
Sasaki E, Tominaga K, Watanabe T, Oshitani N, Higuchi K and Arakawa
T: Relationship between peroxisome proliferator-activated receptor
gamma expression and differentiation of human esophageal squamous
cell carcinoma. Oncol Rep. 13:601–606. 2005.PubMed/NCBI
|
|
17
|
Sawayama H, Ishimoto T, Watanabe M,
Yoshida N, Sugihara H, Kurashige J, Hirashima K, Iwatsuki M, Baba
Y, Oki E, et al: Small molecule agonists of PPAR-γ exert
therapeutic effects in esophageal cancer. Cancer Res. 74:575–585.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang W, Wang R, Zhang Z, Li D and Yut Y:
Enhanced PPAR gamma expression may correlate with the development
of Barrett's esophagus and esophageal adenocarcinoma. Oncol Res.
19:141–147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Al-Taie OH, Graf T, Illert B, Katzenberger
T, Mörk H, Kraus MR, Barthelmes HU, Scheurlen M and Seufert J:
Differential effects of PPAR gamma activation by the oral
antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and
in vivo. J Gastroenterol. 44:919–929. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cui Y, Lu Z, Bai L, Shi Z, Zhao WE and
Zhao B: Beta-Carotene induces apoptosis and up-regulates peroxisome
proliferator-activated receptor gamma expression and reactive
oxygen species production in MCF-7 cancer cells. Eur J Cancer.
43:2590–2601. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Zhao WE, Hu L, Zhao L and Huang
J: Carotenoids inhibit proliferation and regulate expression of
peroxisome proliferators-activated receptor gamma (PPARγ) in K562
cancer cells. Arch Biochem Biophys. 512:96–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao H, Gu H, Zhang H, Li JH and Zhao WE:
PPARγ-dependent pathway in the growth-inhibitory effects of K562
cells by carotenoids in combination with rosiglitazone. Biochim
Biophys Acta. 1840:545–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nguyen BN and Zhao WE: Isolation of
lycopene from the crude extract of red watermelon flesh by
high-speed counter-current chromatograghy. J Zhengzhou Univ (Energ
Sci). 37:43–46. 2016.
|
|
24
|
Yang CM, Lu IH, Chen HY and Hu ML:
Lycopene inhibits the proliferation of androgen-dependent human
prostate tumor cells through activation of PPARγ-LXRα-ABCA1
pathway. J Nutr Biochem. 23:8–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang CM, Lu YL, Chen HY and Hu ML:
Lycopene and the LXRα agonist T0901317 synergistically inhibit the
proliferation of androgen-independent prostate cancer cells via the
PPARγ-LXRα-ABCA1 pathway. J Nutr Biochem. 23:1155–1162. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chellappan SP, Giordano A and Fisher PB:
Role of cyclin dependent kinases and their inhibitors in cellular
differentiation and development. Curr Top Microbiol Immunol.
227:57–103. 1998.PubMed/NCBI
|
|
27
|
Gartel AL and Tyner AL: The
growth-regulatory role of p21 (WAF1/CIP1). Prog Mol Subcell Biol.
20:43–71. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei J, Zhao J, Long M, Han Y, Wang X, Lin
F, Ren J, He T and Zhang H: p21WAF1/CIP1 gene
transcriptional activation exerts cell growth inhibition and
enhances chemosensitivity to cisplatin in lung carcinoma cell. BMC
Cancer. 10:6322010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J,
Wang X, Zhong X and Wang S: Dual high expression of STAT3 and
cyclin D1 is associated with poor prognosis after curative
resection of esophageal squamous cell carcinoma. Int J Clin Exp
Pathol. 7:7989–7998. 2014.PubMed/NCBI
|
|
30
|
Yang GZ, Li L, Ding HY and Zhou JS:
Cyclooxygenase-2 is overexpressed in Chinese esophageal squamous
cell carcinoma, and correlated with NF-kappa B: An
immunohistochemical study. Exp Mol Pathol. 79:214–218. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM
and Zhang ST: Effects of cyclooxygenase-2 on human esophageal
squamous cell carcinoma. World J Gastroenterol. 17:4572–4580. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sugimura A, Kiriyama Y, Nochi H, Tsuchiya
H, Tamoto K, Sakurada Y, Ui M and Tokumitsu Y: Troglitazone
suppress cell growth of myeloid leukemia cell lines by induction of
p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem
Biophys Res Commun. 261:833–837. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han S, Sidell N, Fisher PB and Roman J:
Up-regulation of p21 gene expression by peroxisome
proliferator-activated receptor gamma in human lung carcinoma
cells. Clin Cancer Res. 10:1911–1919. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smith AG, Beaumont KA, Smit DJ, Thurber
AE, Cook AL, Boyle GM, Parsons PG, Sturm RA and Muscat GE: PPAR
gamma agonist attenuate proliferation and modulate Wnt/beta-catenin
signaling in melanoma cells. Int J Biochem Cell Biol. 41:844–852.
2009. View Article : Google Scholar : PubMed/NCBI
|
